Barrier Therapeutics, Inc.

Liarozole receives FDA orphan drug status

Published in FDA Law Weekly, July 22nd, 2004

Barrier Therapeutics, Inc., (BTRX) announced that its drug, Liarozole, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of congenital ichthyosis, a group of debilitating and, in certain cases, life-threatening skin disorders that together affect approximately 40,000 people in the United States.

There are currently no prescription drugs approved for congenital ichthyosis in the U.S. In prior phase II and phase III clinical trials, oral Liarozole, which represents a new concept in treating this condition, was well tolerated and a majority of patients showed marked improvement in their condition. The drug previously...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of FDA Law Weekly

Source: FDA Law Weekly (2004-07-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry